Book CA 19-9 Test in Jaipur

Key facts about the Ca 199 test in Jaipur
Also Known As	Cancer Antigen 19-9, Carbohydrate Antigen 19-9, CA 19-9 Tumour Marker
Sample Type	Blood (Serum)
Fasting Required	No (fasting advisable if co-ordered with liver or glucose tests)
Report Delivery	Within 24 hours
Age Group	Adults
Gender	All
Test Type	Chemiluminescent immunoassay (CLIA) or ELISA
Units	U/mL (Units per millilitre)

The CA 19-9 test is a blood test that measures the level of Cancer Antigen 19-9, a carbohydrate antigen that functions as a tumour marker primarily associated with cancers of the pancreas, bile ducts, gallbladder, and gastrointestinal tract. CA 19-9 is a glycoprotein naturally present on the surface of certain cells lining the digestive system and is shed into the bloodstream in elevated quantities when these cells undergo malignant transformation or when certain benign inflammatory conditions affect the pancreas, liver, or biliary system. The test is most widely recognised as the primary tumour marker for pancreatic cancer, one of the most lethal malignancies worldwide and increasingly diagnosed in India due to rising rates of obesity, Type 2 diabetes, and smoking. While CA 19-9 is not sufficiently sensitive or specific to be used as a standalone screening test, it plays an indispensable role in monitoring treatment response, detecting recurrence after surgery, and assessing disease progression in patients with known pancreatic or biliary tract malignancies. CA 19-9 can also be elevated in benign conditions including pancreatitis, cholestasis, and liver cirrhosis, which is why results must always be interpreted alongside clinical findings and imaging. The test is performed on a small blood sample drawn from a vein and completed in under five minutes.

Doctors prescribe a CA 19-9 test in the following situations: Monitoring treatment response in patients with confirmed pancreatic cancer where serial CA 19-9 measurements assess whether chemotherapy, surgical resection, or radiation is achieving disease control, with falling levels indicating efficacy and rising levels signalling resistance or progression. Detecting recurrence after surgical resection of pancreatic or biliary tract malignancies where a rising CA 19-9 during post-operative surveillance is often the earliest sign of disease returning, frequently preceding clinical symptoms or radiological findings by several weeks. Evaluating suspected pancreatic cancer in patients with new-onset jaundice, upper abdominal pain radiating to the back, unexplained weight loss, and new-onset diabetes in individuals over 50, where elevated CA 19-9 alongside imaging strengthens the case for malignancy. Assessing biliary tract malignancies including cholangiocarcinoma and gallbladder cancer where CA 19-9 is used alongside CEA and imaging to evaluate suspicious biliary strictures and guide decisions regarding further investigation or surgical exploration. Monitoring chronic pancreatitis where periodic CA 19-9 testing helps detect malignant transformation, as chronic pancreatitis is a recognised risk factor for pancreatic ductal adenocarcinoma over time. Assessing mucinous ovarian tumours where CA 19-9 may be elevated alongside CA 125, and where a multi-marker approach improves diagnostic accuracy in evaluating complex pelvic masses.

The CA 19-9 test measures the concentration of Cancer Antigen 19-9 in the blood, expressed in Units per millilitre (U/mL). The universally accepted normal reference range is less than 37 U/mL for adults, with no clinically significant variation by gender or age. Normal (Below 37 U/mL) A result below 37 U/mL is considered within the normal range. In patients under active oncological surveillance, a consistently normal CA 19-9 is reassuring, though clinical correlation with imaging and symptoms remains essential. Mildly Elevated (37 to 200 U/mL) A mildly elevated result may be seen in both malignant and benign conditions including pancreatitis, cholestasis, and liver disease. In the absence of a known malignancy, this range warrants thorough clinical evaluation with abdominal imaging before attributing the elevation to a specific cause. Markedly Elevated (Above 200 U/mL) Markedly elevated levels above 200 U/mL, particularly above 1000 U/mL, are strongly associated with pancreatic or biliary tract malignancy and frequently indicate advanced or metastatic disease. Such levels carry significant prognostic weight and guide the urgency of oncological intervention.

No specific fasting is strictly required for the CA 19-9 test, as food intake does not significantly alter tumour marker concentrations. However, since this test is commonly ordered alongside liver function or blood glucose tests, fasting for 8 to 10 hours is generally recommended to ensure all co-ordered investigations yield accurate results. Certain conditions can transiently elevate CA 19-9 independent of malignancy, including active jaundice, acute pancreatitis, liver cirrhosis, and biliary obstruction. Disclosing these to your doctor before testing ensures your result is interpreted accurately and benign elevation is not misattributed to suspected malignancy. If you are undergoing serial CA 19-9 measurements for cancer monitoring, having each test performed at the same laboratory using the same assay platform improves the reliability of trend interpretation over time. Staying well hydrated before the blood draw facilitates easier venous access and a smooth collection experience.

If you are booking through the SecondMedic platform the CA 19-9 test price in Jaipur can cost you around Rs. 1342. You may also consider booking a comprehensive tumour marker panel that includes CA 19-9 alongside CEA, AFP, and CA 125 for a more complete oncological marker profile at a bundled price on SecondMedic.

SecondMedic offers convenient home sample collection for the CA 19-9 test in Jaipur, making it easy to get tested without visiting a diagnostic centre. Home collection is available free of charge for orders above Rs. 300. A trained phlebotomist will visit your preferred address between 7 AM and 10 PM, seven days a week, including Sundays and public holidays. Your blood sample is processed at NABL-accredited partner laboratories, and your report is delivered within 24 hours directly to your WhatsApp and email.

Our Presence In India

Beyond Jaipur, SecondMedic collects samples for the Ca 199 test in 121 cities across India, served by 35 regional processing labs covering over 4,500 pincodes. Select another city below to see its pricing and partner labs. Home collection is available in every city listed.

Allahabad (Prayagraj)

Vizag (Visakhapatnam)

Mangalore (Dakshina Kannada)

Rourkela (Sundargarh)

Content Reviewed By

This page was medically reviewed by Dr. Kovid Pandey, MBBS, a General Physician, and last reviewed on 10 March 2026. Clinical statements about the Ca 199 test are checked against the references listed below before publication, and the page is re-reviewed whenever test guidance or partner lab protocols change.

Reviewed by:

Dr. Kovid Pandey

MBBS, General Physician

Last Reviewed: 10th Mar 2026

References

The clinical statements on this page are drawn from the sources listed below. Each entry names the publishing body and, where one is available, links to the specific document rather than to the organisation homepage, so any claim on this page can be checked against its source.

Tempero MA et al.: Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, 2021 — doi.org

Locker GY et al.: ASCO 2006 Update of Recommendations for the Use of Tumour Markers in Gastrointestinal Cancer, Journal of Clinical Oncology, 2006 — doi.org

Goonetilleke KS and Siriwardena AK: Systematic Review of Carbohydrate Antigen 19-9 as a Biochemical Marker in the Diagnosis of Pancreatic Cancer, European Journal of Surgical Oncology, 2007 — doi.org

Ballehaninna UK and Chamberlain RS: The Clinical Utility of Serum CA 19-9 in the Diagnosis, Prognosis and Management of Pancreatic Adenocarcinoma, Journal of Gastrointestinal Oncology, 2012 — doi.org

Chaube A et al.: CA 19-9 as a Diagnostic and Prognostic Marker for Pancreatic and Biliary Cancers in the Indian Population, Indian Journal of Surgical Oncology, 2015 — doi.org